Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel ® Radionuclide Therapy ™ (PRnT ™ ) is preparing to open two...
Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT ™ ) with its innovative RadioGel ® technology,...
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel...
Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United...
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating...
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating...
Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) – The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical...
Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology...
Richland, WA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced today that they have appointed Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead...
Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name...